argenx SE (LON:0QW0)

London flag London · Delayed Price · Currency is GBP · Price in EUR
549.20
-2.38 (-0.43%)
At close: Aug 13, 2025
12.15%
Market Cap 29.10B
Revenue (ttm) 2.28B
Net Income (ttm) 934.56M
Shares Out n/a
EPS (ttm) 13.68
PE Ratio 31.14
Forward PE 29.89
Dividend n/a
Ex-Dividend Date n/a
Volume 30,129
Average Volume 19,020
Open 548.40
Previous Close 551.58
Day's Range 544.80 - 552.60
52-Week Range 456.80 - 656.80
Beta -0.01
RSI 56.04
Earnings Date Jul 31, 2025

About argenx SE

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren’s disease, lupus nephropathy, systemic sclerosis, ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 1,599
Stock Exchange London Stock Exchange
Ticker Symbol 0QW0
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.